Today, I am proud to announce Georgiamune Inc. has reached two momentous milestones – Samir Khleif

Today, I am proud to announce Georgiamune Inc. has reached two momentous milestones: IND acceptance of GIM-122, a novel dual-functioning monoclonal antibody, and an oversubscribed $75M Series A financing round co-led by General Catalyst and Parker Institute for Cancer Immunotherapy with additional support from Mubadala Capital Alexandria Venture Investments, Catalio Capital Management CJNV BioVenture, and Verition Fund Management LLC.

I am grateful to my dedicated team for propelling forward our mission to transform cancer and autoimmune patient care. There are exciting developments on Georgiamune’s horizon – such as our first clinical trial in oncology – and I’m honored to be part of it all.

Learn more at www.georgiamune.com

Hear from our partners at General Catalyst about why they invested: Click here

Source: Samir Khleif / Linkedin